Advantages and limits of targeted radionuclide therapy with somatostatin antagonists

Elif Hindie; Clement Morgat; Paolo Zanotti-Fregonara; Magalie Haissaguerre; Laurence Bordenave; Antoine Tabarin

doi:10.2967/jnumed.117.202630

Advantages and limits of targeted radionuclide therapy with somatostatin antagonists

Elif Hindie, Clement Morgat, Paolo Zanotti-Fregonara, Magalie Haissaguerre, Laurence Bordenave, Antoine Tabarin

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	546-547
Number of pages	2
Journal	Journal of Nuclear Medicine
Volume	59
Issue number	3
DOIs	https://doi.org/10.2967/jnumed.117.202630
State	Published - Mar 1 2018

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnumed.117.202630

Cite this

@article{da47191bc8ae4da684ba4841d31d712c,

title = "Advantages and limits of targeted radionuclide therapy with somatostatin antagonists",

author = "Elif Hindie and Clement Morgat and Paolo Zanotti-Fregonara and Magalie Haissaguerre and Laurence Bordenave and Antoine Tabarin",

year = "2018",

month = mar,

day = "1",

doi = "10.2967/jnumed.117.202630",

language = "English (US)",

volume = "59",

pages = "546--547",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "3",

}

TY - JOUR

T1 - Advantages and limits of targeted radionuclide therapy with somatostatin antagonists

AU - Hindie, Elif

AU - Morgat, Clement

AU - Zanotti-Fregonara, Paolo

AU - Haissaguerre, Magalie

AU - Bordenave, Laurence

AU - Tabarin, Antoine

PY - 2018/3/1

Y1 - 2018/3/1

UR - http://www.scopus.com/inward/record.url?scp=85044173980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044173980&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.202630

DO - 10.2967/jnumed.117.202630

M3 - Letter

C2 - 28986513

AN - SCOPUS:85044173980

SN - 0161-5505

VL - 59

SP - 546

EP - 547

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 3

ER -

Advantages and limits of targeted radionuclide therapy with somatostatin antagonists

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this